Quote | C4 Therapeutics Inc. (NASDAQ:CCCC)
Last: | $4.53 |
---|---|
Change Percent: | -0.44% |
Open: | $4.55 |
Close: | $4.55 |
High: | $4.6 |
Low: | $4.48 |
Volume: | 157,231 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | C4 Therapeutics Inc. (NASDAQ:CCCC)
2024-06-13 11:33:07 ET Summary C4 Therapeutics focused on protein degraders, with recent financial updates and guidance for 2024 catalysts. The pipeline includes Cemsidomide for multiple myeloma and CFT1946 for melanoma, with ongoing dose escalation trials. Financially, CCCC r...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...
Message Board Posts | C4 Therapeutics Inc. (NASDAQ:CCCC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidom...